Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

HO CHI MINH CITY, Vietnam, September 3 /PRNewswire/ --

- NIIT Students and IT Professionals in Vietnam and Other Asia Pacific Markets to Gain Skills in the Latest and Most Advanced Technologies

Sun Microsystems, a leading provider of advanced network computing systems, software and IT-related solutions, and NIIT, a leading Global Talent Development Corporation have announced a partnership to offer training on Sun technologies to students in Vietnam. This partnership will also be expanded to other Asia Pacific markets including Indonesia, Thailand and Malaysia through NIIT's network of IT training centers in the Asia Pacific region.

CALGARY, Canada, September 2 /PRNewswire/ --

<< 50 Per Cent Interest and Operator of Gryphon Marin License Area, Adjacent to Existing Operations Offshore Gabon >>

Canada Addax Petroleum Corporation ("Addax Petroleum" or the "Corporation") (TSX:AXC and LSE:AXC), today announced that it has acquired a 50 per cent interest in the Gryphon Marin license area subject to final Government of Gabon approval. Addax Petroleum will become operator of the Gryphon Marin license area which is immediately west of the Corporation's Iris Marin and Ibekelia license areas and immediately north of the Corporation's Etame Marin license, offshore Gabon.

CARLSBAD, California, September 2 /PRNewswire/ --

- Important Studies Presented at the European Society of Cardiology Continue to Bring Attention to Innovative Technology

Ablation Frontiers, Inc., announced today that two important studies, involving its innovative atrial fibrillation ablation products were presented by Dr. Lucas Boersma of the St. Antonius Hospital in Nieuwegein, Netherlands at the European Society of Cardiology (ESC) congress. One of the world's most prestigious scientific meetings for cardiologists, the ESC meetings took place from August 30 - September 3 in Munich, Germany.

CALGARY, Canada, September 2 /PRNewswire/ --

- Multiple Presentations Included Resverlogix Data

- TSX Exchange Symbol: RVX

SAN RAMON, California, September 2 /PRNewswire/ --

Achievo(R) Corporation, a software outsourcing and information technology services provider, is proud to announce it is working with The InnoVest Group, LC, a US based management consulting and joint venture firm, to provide IT outsourcing (ITO) services and solutions in the Middle East, initially in Saudi Arabia, UAE, Bahrain, and Jordan. Achievo offers its clients local account management and project delivery capabilities through its regional offices in Japan, North America, Europe and Greater China that are integrated with and supported by its offshore delivery centers in China and its headquarters in the United States.

WELLESLEY HILLS, Massachusetts, September 2 /PRNewswire/ --

Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all pharmaceutical intellectual property will be sold at a sealed bid auction on October 10, 2008.

With SRx-503, Spherics has developed an improved version of a first and second line treatment for Parkinson's disease. Current global sales exceed US$700 million (approx. US$600 million US only), despite a severe side-effect profile (including motor fluctuations and GI and CNS AE's) and compliance issues (3x daily dosing). SRx-503 maintains a more stable release profile, bypasses the stomach to alleviate GI side effects and requires dosing only once daily.